The aim of this study was to provide a new effective carrier for rescuing the sensitivity of drug-resistant in breast cancer cells. Nano-gold micelles loaded with Dox and Elacridar (FP-ssD@A-E) were chemically synthesised. With the increase in the amount of Dox and Elacridar, the encapsulation rate of FP-ssD@A-E gradually increased, and the drug loading rate gradually decreased. FP-ss@A-E had a sustained-release effect. Dox, Elacridar, FP-ss@AuNPs, and FP-ssD@A-E significantly improved cell apoptosis, in which, FP-ssD@A-E was the most significant. FP-ssD@A-E significantly decreased the cell viability and improved the Dox uptake. The levels of VEGFR-1, P-gp, IL-6, and i-NOS were significantly decreased after Dox, Dox + Elacridar, FP-ss@AuNPs, and FP-ssD@A-E treatment. It was worth noting that FP-ssD@A-E had the most significant effects. The prepared FP-ssD@A-E micelles, which were spherical in shape, uniform in particle size distribution, and had good drug loading performance and encapsulation efficiency.

中文翻译：

---

载有 Dox 和 Elacridar 的纳米金胶束用于逆转乳腺癌的耐药性。

本研究旨在为挽救乳腺癌细胞耐药敏感性提供一种新的有效载体。化学合成了载有 Dox 和 Elacridar (FP-ssD@AE) 的纳米金胶束。随着Dox和Elacridar用量的增加，FP-ssD@AE的包封率逐渐增加，载药量逐渐降低。FP-ss@AE 具有缓释作用。Dox、Elacridar、FP-ss@AuNPs和FP-ssD@AE显着改善细胞凋亡，其中FP-ssD@AE最显着。FP-ssD@AE 显着降低了细胞活力并提高了 Dox 摄取。在 Dox、Dox + Elacridar、FP-ss@AuNPs 和 FP-ssD@AE 处理后，VEGFR-1、P-gp、IL-6 和 i-NOS 的水平显着降低。值得注意的是，FP-ssD@AE 的效果最为显着。